{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:50:17Z","timestamp":1784922617467,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Women with multiple sclerosis (MS) may face challenges related to managing reproduction, pregnancy, and menopause while simultaneously managing their disease. The purpose of this scoping review was to map the literature broadly related to topics relevant to women's health in MS to inform the clinical and research communities about the existing types and sources of evidence and knowledge gaps. Apart from coverage of topics within the field of women's health, we were interested in potential gaps related to geographic and racial and ethnic diversity. We also aimed to understand the degree of inclusion of women with progressive MS in this research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched the EMBASE and Ovid Medline databases from 1980 until November 23, 2020. We included case-control and cohort studies, clinical trials and case series published in any language, conducted in women with MS, clinically isolated syndrome, or radiologically isolated syndrome, that addressed women's health. Two reviewers independently screened abstracts and full-text reports for study inclusion, and completed data extraction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 112,106 citations screened, 1,041 underwent full-text review and 353 met the inclusion criteria. The number of studies regarding women's health has increased exponentially over time. Almost half of the studies were conducted (at least in part) in Europe, while 21.7% were conducted in North America; only one study was conducted in Africa. Most studies did not report the race or ethnicity of their participants (<jats:italic>n<\/jats:italic> = 308, 87.2%). Among the 353 studies, 509 topics were reported as some studies addressed more than one topic. Over one-third of these focused on pregnancy (<jats:italic>n<\/jats:italic> = 201, 37.2%), followed by fetal\/neonatal outcomes (14.4%) and sexual dysfunction (10%). Among the 201 studies that focused on pregnancy, only 51 (25.4%) included participants with progressive MS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This review identifies important knowledge gaps related to women's health in MS and particularly the need for future studies to include participants with a broader range of races and ethnicities, with progressive MS, and living in Asia-Pacific and African regions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2021.812147","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:13:43Z","timestamp":1643613223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Women's Health in Multiple Sclerosis: A Scoping Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Lindsay","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huah Shin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"O'Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Pat","family":"Harnegie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tintore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"B1","first-page":"73","article-title":"Women's Health. Report of the public health service task force on women's health issues","volume":"100","author":"Kirschstein","year":"1985","journal-title":"Public Health Rep"},{"key":"B2","volume-title":"Women's Health Research: Progress, Pitfalls, and Promise","year":"2010"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler."},{"key":"B4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1017\/cjn.2017.301","article-title":"Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan","volume":"45","author":"Al-Sakran","year":"2018","journal-title":"Can J Neurol Sci Le J Can des Sci Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1212\/WNL.0000000000005331","article-title":"Temporal trends in multiple sclerosis prevalence and incidence in a large population","volume":"90","author":"Rotstein","year":"2018","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1001\/jama.294.21.2751","article-title":"Manifestations of chronic disease during pregnancy","volume":"294","author":"Kaaja","year":"","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/jwh.2012.3733","article-title":"Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials","volume":"21","author":"Coakley","year":"2012","journal-title":"J Womens Health (Larchmt)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3389\/fneur.2021.680912","article-title":"Is It Time for quotas to achieve racial and ethnic representation in multiple sclerosis trials?","volume":"12","author":"Mateen","year":"2021","journal-title":"Front Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaneurol.2014.79","article-title":"Inadequacy of clinical trial designs and data to control for the confounding impact of race\/ethnicity in response to treatment in multiple sclerosis","volume":"71","author":"Avasarala","year":"2014","journal-title":"JAMA Neurol."},{"key":"B11","unstructured":"Atlas of MS2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-156-1-201201030-00006","article-title":"Distinguishing case series from cohort studies","volume":"156","author":"Dekkers","year":"2012","journal-title":"Ann Intern Med."},{"key":"B15","year":"2010"},{"key":"B16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/AOG.0000000000003727","article-title":"Multiple sclerosis: clinical updates in women's health care primary and preventive care review","volume":"135","author":"Fang","year":"","journal-title":"Obstet Gynecol"},{"key":"B17","unstructured":"Women's Health Multiple Sclerosis.2019"},{"key":"B18","unstructured":"GiesserB\n          Overview of MS Women's Health Issues.2019"},{"key":"B19","unstructured":"Women's Health Week Partners With MS Australia to Spotlight Multiple Sclerosis and Women's Health2021"},{"key":"B20","unstructured":"Maternal Newborn Health- UNICEF DATA2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clim.2013.01.008","article-title":"Effects of pregnancy and breastfeeding on the multiple sclerosis disease course","volume":"149","author":"Langer-Gould","year":"","journal-title":"Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.2018.17716","article-title":"Increasing the participation of pregnant women in clinical trials","volume":"320","author":"Heyrana","year":"2018","journal-title":"JAMA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1097\/GME.0000000000001213","article-title":"NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy","volume":"25","author":"Utian","year":"2018","journal-title":"Menopause."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1212\/WNL.0000000000003176","article-title":"Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis","volume":"86","author":"Bove","year":"2016","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(15)00322-1","article-title":"Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Voskuhl","year":"","journal-title":"Lancet Neurol"},{"key":"B28","unstructured":"Contraceptive Use by Method2019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/humrep\/deaa090","article-title":"International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology (2012)","volume":"35","author":"de Mouzon","year":"2020","journal-title":"Hum Reprod."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/humrep\/dew151","article-title":"Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE","volume":"31","author":"Kupka","year":"2016","journal-title":"Hum Reprod"},{"key":"B31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1179\/2050854914Y.0000000027","article-title":"The breast cancer epidemic: 10 facts","volume":"81","author":"Schneider","year":"2014","journal-title":"Linacre Q"},{"key":"B32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jnma.2020.03.002","article-title":"A review of cervical cancer: incidence and disparities","volume":"112","author":"Buskwofie","year":"2020","journal-title":"J Natl Med Assoc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1212\/WNL.0b013e3182918cc2","article-title":"Incidence of multiple sclerosis in multiple racial and ethnic groups","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1017\/cjn.2015.36","article-title":"Incidence of multiple sclerosis and related disorders in Asian populations of British Columbia","volume":"42","author":"Lee","year":"2015","journal-title":"Can J Neurol Sci Le J Can des Sci Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000484090","article-title":"Increasing incidence and prevalence of multiple sclerosis in Puerto Rico (2013-2016)","volume":"49","author":"Chinea","year":"2017","journal-title":"Neuroepidemiology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/1352458519887328","article-title":"Race and ethnicity on MS presentation and disease course","volume":"26","author":"Amezcua","year":"2020","journal-title":"Mult Scler."},{"key":"B38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.fertnstert.2009.10.047","article-title":"Racial and ethnic differences in reproductive potential across the life cycle","volume":"93","author":"Butts","year":"2010","journal-title":"Fertil Steril."},{"key":"B39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual report to the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)\u2013associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"JNCI J Natl Cancer Inst."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"","journal-title":"Lancet Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","article-title":"Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study","volume":"26","author":"Naismith","year":"","journal-title":"Mult Scler J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B44","unstructured":"Atlas of MS2013"},{"key":"B45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2105\/AJPH.2009.160804","article-title":"Disparities in health insurance coverage, access, and outcomes for individuals in same-sex versus different-sex relationships, 2000\u20132007","volume":"100","author":"Buchmueller","year":"2010","journal-title":"Am J Public Health."},{"key":"B46","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2105\/AJPH.2007.130336","article-title":"Demonstrating the importance and feasibility of including sexual orientation in public health surveys: health disparities in the Pacific Northwest","volume":"100","author":"Dilley","year":"2010","journal-title":"Am J Public Health."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10461-007-9299-3","article-title":"Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review","volume":"12","author":"Herbst","year":"2008","journal-title":"AIDS Behav."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.812147\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:13:49Z","timestamp":1643613229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.812147\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":47,"alternative-id":["10.3389\/fneur.2021.812147"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.812147","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"article-number":"812147"}}